Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
J Cutan Pathol ; 49(1): 34-41, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34292611

RESUMO

BACKGROUND: As more people become vaccinated against the SARS-CoV-2 virus, reports of delayed cutaneous hypersensitivity reactions are beginning to emerge. METHODS: In this IRB-approved retrospective case series, biopsy specimens of potential cutaneous adverse reactions from the Pfizer-BioNTech or Moderna mRNA vaccine were identified and reviewed. Clinical information was obtained through the requisition form, referring clinician, or medical chart review. RESULTS: Twelve cases were included. Histopathological features from two injection-site reactions showed a mixed-cell infiltrate with eosinophils and a spongiotic dermatitis with eosinophils. Three biopsy specimens came from generalized eruptions that showed interface changes consistent with an exanthematous drug reaction. Three biopsy specimens revealed a predominantly spongiotic pattern, consistent with eczematous dermatitis. Small-vessel vascular injury was seen in two specimens, which were diagnosed as urticarial vasculitis and leukocytoclastic vasculitis, respectively. There were two cases of new-onset bullous pemphigoid supported by histopathological examination and direct immunofluorescence studies. Eosinophils were seen in 10 cases. CONCLUSIONS: Dermatopathologists should be aware of potential cutaneous adverse reactions to mRNA-based COVID-19 vaccines. Histopathological patterns include mixed-cell infiltrates, epidermal spongiosis, and interface changes. Eosinophils are a common finding but are not always present. Direct immunofluorescence studies may be helpful for immune-mediated cutaneous presentations such as vasculitis or bullous pemphigoid.


Assuntos
Vacinas contra COVID-19/efeitos adversos , COVID-19/prevenção & controle , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Hipersensibilidade Tardia/patologia , Vacina de mRNA-1273 contra 2019-nCoV/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Vacina BNT162/efeitos adversos , Biópsia/métodos , COVID-19/diagnóstico , COVID-19/imunologia , COVID-19/virologia , Dermatite/etiologia , Dermatite/patologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia , Eosinófilos/patologia , Feminino , Técnica Direta de Fluorescência para Anticorpo/métodos , Humanos , Hipersensibilidade Tardia/etiologia , Masculino , Pessoa de Meia-Idade , Penfigoide Bolhoso/diagnóstico , Penfigoide Bolhoso/patologia , Estudos Retrospectivos , SARS-CoV-2/genética , SARS-CoV-2/imunologia , Pele/patologia , Vasculite/induzido quimicamente , Vasculite/patologia
4.
Am J Dermatopathol ; 43(10): 746-749, 2021 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-34086644

RESUMO

ABSTRACT: Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a morbilliform eruption during a clinical trial for treatment of metastatic pancreatic adenocarcinoma. Histopathological findings demonstrated diminished elastic fibers in the papillary dermis, associated with a histiocyte-rich infiltrate and increased dermal mucin, features that should clue the dermatopathologist to this condition.


Assuntos
Adenocarcinoma/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Erupção por Droga/patologia , Neoplasias Pancreáticas/patologia , Adenocarcinoma/secundário , Anticorpos Monoclonais/administração & dosagem , Derme/patologia , Erupção por Droga/diagnóstico , Erupção por Droga/etiologia , Erupção por Droga/metabolismo , Quimioterapia Combinada/efeitos adversos , Tecido Elástico/patologia , Histiócitos/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Mucinas/metabolismo , Nivolumabe/administração & dosagem
6.
Am J Dermatopathol ; 43(2): 112-118, 2021 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-32618707

RESUMO

BACKGROUND: Dermatopathologists sometimes encounter patients with features of psoriasis vulgaris and additional changes of eczematous dermatoses. These cases are challenging to diagnose, and the clinical implications are unclear. In the age of targeted therapy, it is important to improve our understanding of these findings so that patients are managed appropriately. OBJECTIVE: To characterize the clinical characteristics, histopathological features, diagnostic workup, successful treatment, and outcomes of patients with overlapping histopathologic features of psoriasis vulgaris and eczema. METHODS: We conducted a retrospective chart review of 20 patients who had received the histopathologic diagnosis of psoriasis vulgaris with eczematous changes noted on skin biopsy. A database that included information about clinical characteristics, comorbidities, histopathological features, diagnostic workup, treatment modalities, and outcomes was created and analyzed. RESULTS: Twenty patients were included in this study, with an average age of 57.3 years. After clinicopathologic correlation, most patients were diagnosed with psoriasis (85%), and the remainder were determined to have an eczematous dermatitis. Thirty-five percent of patients were diagnosed with allergic contact dermatitis, either in combination with psoriasis (6 patients) or alone (1 patient). Topical glucocorticoids were the most common effective therapy used, and systemic therapies were required in nearly half of patients for successful treatment. CONCLUSION: This study offers insights into the clinically and histopathologically challenging diagnosis of psoriasis vulgaris with eczematous changes and offers the diagnostic term "eczematized psoriasis" to describe these patients. The presence of allergic contact dermatitis should be considered in these patients.


Assuntos
Dermatite Alérgica de Contato/patologia , Eczema/patologia , Psoríase/patologia , Pele/patologia , Administração Cutânea , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Produtos Biológicos/administração & dosagem , Biópsia , Bases de Dados Factuais , Dermatite Alérgica de Contato/tratamento farmacológico , Eczema/tratamento farmacológico , Feminino , Glucocorticoides/administração & dosagem , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Psoríase/tratamento farmacológico , Indução de Remissão , Estudos Retrospectivos , Pele/efeitos dos fármacos , Resultado do Tratamento , Adulto Jovem
9.
JAAD Case Rep ; 6(10): 1069-1071, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33005709
13.
Am J Dermatopathol ; 42(2): 75-85, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31990699

RESUMO

Direct immunofluorescence (DIF) remains a valuable tool that may be underused because of perceived challenges in the interpretation, limitations, and processing of DIF specimens. The aim of this review is to provide a practical guide for appropriately incorporating DIF in a variety of clinical diseases, such as autoimmune blistering disorders. In vasculitis, the role of DIF continues to evolve, particularly in the setting of IgA vasculitis. Although typically not indicated for the workup of connective tissue disease, DIF may be helpful in cases with negative serologies, nondiagnostic histologic findings, or scarring alopecia. Practical pearls for biopsy technique, specimen handling, and storage are also discussed.


Assuntos
Técnica Direta de Fluorescência para Anticorpo/métodos , Dermatopatias/diagnóstico , Doenças Autoimunes/diagnóstico , Vesícula/diagnóstico , Doenças do Tecido Conjuntivo/diagnóstico , Humanos , Vasculite/diagnóstico
14.
J Drugs Dermatol ; 18(12): 1276-1279, 2019 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-31860218

RESUMO

Lichen planopilaris (LPP) is a cicatricial alopecia that often causes permanent hair loss. Pioglitazone, a peroxisome proliferator activated receptor-gamma (PPAR- γ) agonist, has demonstrated immunomodulatory properties that may offer an effective treatment modality. This retrospective analysis describes 23 patients with LPP treated with adjunctive pioglitazone. Most (18/25) demonstrated significant reduction in patient-reported symptoms and clinical signs of inflammation. No adverse effects were reported. J Drugs Dermatol. 2019;18(12):1276-1279.


Assuntos
Líquen Plano/tratamento farmacológico , PPAR gama/agonistas , Pioglitazona/administração & dosagem , Adulto , Idoso , Feminino , Humanos , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/farmacologia , Masculino , Pessoa de Meia-Idade , Pioglitazona/farmacologia , Estudos Retrospectivos , Resultado do Tratamento
15.
Adv Anat Pathol ; 26(1): 40-55, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30418180

RESUMO

Inflammatory skin diseases encompass a vast array of conditions. The field continues to expand and evolve with resurgence of conditions, through newly recognized medication adverse effects, and via more detailed descriptions of known dermatoses. The importance of clinicopathologic correlation and an up to date knowledge of dermatologic conditions cannot be overstated. This review focuses on an array of recent important developments in the histologic diagnosis of inflammatory conditions that affect the skin.


Assuntos
Doenças Autoimunes/patologia , Inflamação/patologia , Dermatopatias/patologia , Pele/patologia , Anticorpos/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Antígeno B7-H1/imunologia , Antígeno CTLA-4/imunologia , Humanos , Inflamação/tratamento farmacológico , Dermatopatias/diagnóstico , Dermatopatias/tratamento farmacológico
16.
Am J Dermatopathol ; 41(5): 347-349, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30422830

RESUMO

"Eosinophils are absent in psoriasis" has been dogma for generations; yet, there is little published to support this statement. Two recent studies examining the presence of eosinophils in psoriasis came to contrasting conclusions. We reviewed skin biopsies from 50 patients with clinically confirmed cases of psoriasis vulgaris to characterize the histologic features, with a focus on the number of eosinophils in the dermis. We noted the presence of eosinophils in nearly half of our study population (n = 23, 46.0%). There was no significant association between the presence of eosinophils and degree of spongiosis (P = 0.405). Eosinophil density ranged from 0 to 8 per tissue section. The mean average eosinophil density was 1.04 (range: 0-8) per tissue section. Among cases with eosinophils, there were 73.9% (n = 17/23) of cases with 1-2 eosinophils, and 26.1% (n = 6) with 3-8 eosinophils. Mild to moderate spongiosis was noted in the majority of cases (n = 48; 96.0%). Eosinophils were only present in psoriasis cases with evidence of spongiosis (n = 23; 47.9%). We conclude that eosinophils are not an uncommon finding in the dermis of psoriasis vulgaris, although the number is often few. The presence of eosinophils should not preclude a diagnosis of psoriasis, particularly if other histologic features are supportive.


Assuntos
Eosinófilos/patologia , Psoríase/patologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
17.
Rheumatol Int ; 38(12): 2329-2335, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30327865

RESUMO

Systemic lupus erythematosus (SLE) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV) overlap syndrome is an inflammatory disorder with a mixed presentation that is characterized by clinical features of both SLE and AAV. Although renal disease predominates, any organ system in the body may be affected. Neurologic manifestation in patients with SLE-AAV overlap syndrome is rare and has only been previously documented as cerebral ischemia. We report a patient with SLE-AAV overlap syndrome diagnosed based on clinical, serologic and biopsy-proven histologic findings who presented with subarachnoid hemorrhage (SAH) secondary to ruptured right anterior cerebral artery aneurysm. To the authors' knowledge, this is the first reported case of SLE-AAV overlap syndrome diagnosed in a patient with a SAH due to an intracranial aneurysm. Neurologic involvement in patients with SLE-AAV overlap syndrome is uncommon and has not been well-studied. Clinicians who encounter patients with neurologic signs that present with symptoms and a serologic profile that correspond to both SLE and AAV criteria, should consider the association between SLE-AAV overlap syndrome and a hemorrhagic stroke, specifically SAH.


Assuntos
Aneurisma Roto/etiologia , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações , Aneurisma Intracraniano/complicações , Lúpus Eritematoso Sistêmico/complicações , Hemorragia Subaracnóidea/etiologia , Corticosteroides/administração & dosagem , Adulto , Aneurisma Roto/diagnóstico por imagem , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/sangue , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/terapia , Anticorpos Anticitoplasma de Neutrófilos/sangue , Biomarcadores/sangue , Biópsia , Angiografia Cerebral , Feminino , Humanos , Imunossupressores/administração & dosagem , Aneurisma Intracraniano/diagnóstico por imagem , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/terapia , Troca Plasmática , Hemorragia Subaracnóidea/diagnóstico por imagem , Síndrome , Resultado do Tratamento
20.
Dermatol Online J ; 24(12)2018 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-30677801

RESUMO

The term, acquired perforating dermatoses (APD), represents a group of skin conditions that develop in adulthood and are characterized by transepidermal elimination of dermal connective tissue. This appears clinically as a papulonodule with a keratotic core. Although APD is typically associated with diabetes mellitus, chronic renal failure, and several other conditions causing generalized pruritus, there have been reports in the literature describing an association of APD with select drugs including sorafenib. We present a case of acquired perforating dermatosis in a patient with HIV and hepatocellular carcinoma undergoing treatment with sorafenib.


Assuntos
Antineoplásicos/efeitos adversos , Doenças do Colágeno/induzido quimicamente , Dermatopatias/induzido quimicamente , Sorafenibe/efeitos adversos , Idoso , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/tratamento farmacológico , Doenças do Colágeno/diagnóstico , Doenças do Colágeno/patologia , Infecções por HIV/complicações , Humanos , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/tratamento farmacológico , Masculino , Dermatopatias/diagnóstico , Dermatopatias/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...